BioMedNewsBreaks

WednesdayJun 25, 2025 10:14 am

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Partners with Endlink to Advance Hospital Data Integration

HealthLynked (OTCQB: HLYK), a healthcare technology and patient engagement company, has announced a strategic partnership with Endlink, a data integration firm led by Rubén Viera. The alliance aims to enhance EMR connectivity and workflow automation across hospital systems, building on Endlink's success in Puerto Rico, where its platform serves over 300,000 members and supports two major hospital systems. Viera, a former executive at McKesson and Greenway Health, brings over 25 years of experience in healthcare IT and will help expand HealthLynked’s capabilities in real-time data integration and patient-centered care. The collaboration also creates opportunities to deploy HealthLynked's tools—like AI-driven insights…

Continue Reading

WednesdayJun 25, 2025 9:15 am

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) Expands Fingerprint Drug Testing Across Scandinavia with Spjotgard Partnership

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology firm specializing in non-invasive drug screening, reported continued success in its partnership with Spjotgard, a Scandinavian distributor. The collaboration is accelerating adoption of INBS’ fingerprint-based Drug Screening System across Sweden, Norway, and Denmark, with Finland showing rising interest. The technology offers a less invasive, hygienic alternative to urine and saliva tests, delivering results in under 10 minutes and gaining traction in sectors like logistics, education, and criminal justice. Spjotgard’s growing regional presence and strategic alliances position INBS to scale further in Northern Europe. To view the full article, visit https://ibn.fm/meqb1 About Intelligent…

Continue Reading

TuesdayJun 24, 2025 3:28 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar 

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications. To view the full press release, visit https://ibn.fm/cizlr About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of…

Continue Reading

TuesdayJun 24, 2025 2:46 pm

BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model 

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal…

Continue Reading

TuesdayJun 24, 2025 9:10 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Taps IBN to Lead Corporate Communications Amid Drug Advancements and Subsidiary Launch

NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, has engaged IBN to manage its corporate communications strategy. NRx is advancing two FDA-designated therapies—NRX-100 and NRX-101—with an NDA underway for NRX-100 and additional regulatory filings in progress. The company also launched HOPE Therapeutics, a subsidiary focused on building a national psychiatric care network, with plans for a public spin-out. IBN will leverage its extensive media portfolio to expand investor awareness and outreach. To view the full press release, visit https://ibn.fm/22Xzx About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics…

Continue Reading

MondayJun 23, 2025 10:00 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at iAccess Alpha Virtual Summer Conference

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, announced that CEO Robert Eno and CFO Timothy Cruickshank will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. The executives will also conduct virtual one-on-one meetings with institutional investors during the event. To view the full press release, visit https://ibn.fm/3aL7w About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions.…

Continue Reading

MondayJun 23, 2025 9:20 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s Priority Voucher for NRX-100 Ketamine Formulation

NRx Pharmaceuticals (NASDAQ: NRXP) has filed for the newly launched FDA Commissioner’s National Priority Voucher (CNPV) program, seeking accelerated review for NRX-100, its preservative-free intravenous ketamine formulation. The company believes NRX-100 meets all criteria outlined by FDA Commissioner Marty Makary, who announced the voucher program on June 17, 2025, to prioritize treatments aligned with urgent U.S. health needs—including suicidal depression and PTSD. NRx has already submitted the chemistry, manufacturing, and controls (CMC) portion of its application and received FDA feedback, placing it on track for potential accelerated review of its full New Drug Application (NDA) by late 2025. If granted,…

Continue Reading

MondayJun 23, 2025 9:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone

Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and scale-up for AVERSA Fentanyl, its abuse-deterrent transdermal patch developed in partnership with Kindeva. The report highlights this milestone as a key inflection point that enables Nutriband to initiate production of clinical supplies and proceed with its planned Investigational New Drug ("IND") application for a Phase 1 trial. The AVERSA program follows the 505(b)(2) regulatory pathway and requires only a single Phase 1 study,…

Continue Reading

FridayJun 20, 2025 9:30 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection

HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam’s plans to improve access to timely, remote cardiac care. When symptoms arise, patients use the app-guided system to record a 30-second ECG, which is automatically uploaded to the cloud for physician review in the context of medical history. The company will soon launch an Early Access Program to engage early adopters and providers ahead of broader commercialization. This foundational…

Continue Reading

WednesdayJun 18, 2025 10:45 am

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia

Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste management provider, will implement INBS’ Intelligent Fingerprinting Drug Screening System across its New South Wales operations. Covering over 20 remote land clearing and green waste sites, this marks MWS’s first shift to in-house, on-site drug testing for pre-employment, random, and for-cause purposes. The fingerprint-based system delivers non-invasive results in under ten minutes, enabling rapid safety decisions without disrupting field operations. INBS continues to expand its reach into safety-critical industries, with its scalable, sweat-based drug testing now in use by over 450 organizations across 24 countries.…

Continue Reading